Drug Profile
Protein C - Hyland Immuno
Alternative Names: Ceprotin; Protein C; Protein C concentrate; TAK 662Latest Information Update: 27 Jun 2023
Price :
$50
*
At a glance
- Originator Hyland Immuno
- Developer Takeda
- Class Anticoagulants; Antithrombotics; Biological factors; Blood proteins; Enzyme precursors; Glycoproteins
- Mechanism of Action Protein C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Protein C deficiency
Most Recent Events
- 11 May 2023 Preregistration for Protein C deficiency (In adolescents, In children, In the elderly, In adults) in Japan (IV)
- 30 Aug 2021 Phase-I/II clinical trials in Protein C deficiency (In adolescents, In adults, In children, In the elderly) in Japan (IV) (NCT04984889)
- 02 Aug 2021 Takeda plans a phase I/II trial for Protein C deficiency in Japanese population, in August 2021 (IV, Infusion) (NCT04984889)